Glial fibrillary acidic protein; Intermediate filament protein; Astrocyte; gfapl; DKFZp459C0729; MGC139638; FLJ45472; AI836096; GFAP antibody

For Research Use Only. Not for use in diagnostic procedures.

Monoclonal

IgG1

S206A-8

Mouse

Protein G Purified

1mg/mL (lot specific)

-20 degree C

Small volumes of anti-GFAP antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Background Info: Detects a 50kDa protein in WB. Cross-reacts with GFAP-R416W and other GFAP mutant proteins.

Scientific Background: The 50 kDa type III intermediate filament protein glial fibrillary acidic protein (GFAP) is a major structural component of astrocytes. GFAP associates with the calcium binding protein annexin II-p2 and S-100. Association with these proteins together with phosphorylation regulates GFAP polymerization. Astroycytes respond to brain injury by proliferatin (astrogliosis), and one of the first events to occur during astrocyte proiliferation is increased GFAP expression. Interestingly, antibodies to GFAP have been detected in individuals with dementia.

Neuroscience

Western Blot (WB), Immunocytochemistry (ICC), Immunohistochemistry (IHC)

1:1000 WB

Western Blot analysis of Rat Brain Membrane showing detection of GFAP protein using Mouse Anti-GFAP Monoclonal Antibody, Clone S206A-8. Primary Antibody: Mouse Anti-GFAP Monoclonal Antibody at 1:250.

49,508 Da[Similar Products]

glial fibrillary acidic protein

glial fibrillary acidic protein

Glial fibrillary acidic protein

GFAP??[Similar Products]

GFAP_HUMAN

This gene encodes one of the major intermediate filament proteins of mature astrocytes. It is used as a marker to distinguish astrocytes from other glial cells during development. Mutations in this gene cause Alexander disease, a rare disorder of astrocytes in the central nervous system. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Oct 2008]

GFAP: a class-III intermediate filament protein. A cell-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells. Mutations in this gene cause Alexander disease, a rare disorder of astrocytes in the central nervous system. An additional transcript variant isoform has been described, but its full length sequence has not been determined.

Protein type: Cytoskeletal

Chromosomal Location of Human Ortholog: 17q21

Cellular Component: membrane; cytoplasm; intermediate filament; cytosol

Molecular Function: integrin binding; structural constituent of cytoskeleton; kinase binding

Biological Process: Bergmann glial cell differentiation; extracellular matrix organization and biogenesis; regulation of neurotransmitter uptake; response to wounding; intermediate filament organization; neurite regeneration; astrocyte development

Disease: Alexander Disease

1. Velasco M.E., et al. (1980) Cancer. 45:484. 2. Bonnin J.M., et al. (1984) Acta Neuropathology. 62:185. 3. Lee VM-Y., et al. (1984) J. Neurochem. 42:25-32 (1984). 4. Trojanowski JQ et al. (1986) J. Neurochem. 6(3): 650-660 (1986). 5. Schmidt ML et al; Lab Invest 56:282-294 (1987). 6. Kosik KS et al; Neuron 1:817-825 (1988). 7. Schmidt ML et al; Lab Invest 59:460-466 (1988). 8. Mokuna, K, et al: J Neurosci Res 23:396 (1989). 9. Molenaar, et al; Exp Neurology 108:1-9 (1990). 10. Tohyama T et al; Am J Pathol, 142:871-882 (1993). 11. Tohyama T et al; Am J Pathol 142:883-892 (1993). 12. Thilenius, A.R.B., et al; J. Immunol. 162(2): 643-650 (1999).

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.